NEW YORK (GenomeWeb) – CareFirst Blue Cross Blue Shield said today that it will cover Exosome Diagnostics' ExoDx Prostate IntelliScore (EPI) prostate cancer test based on the results of an evidence development study launched last year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.